Sight Sciences, Inc. (NASDAQ:SGHT) Shares Sold by Jackson Square Partners LLC

Jackson Square Partners LLC lessened its stake in Sight Sciences, Inc. (NASDAQ:SGHT) by 74.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 230,997 shares of the company’s stock after selling 687,062 shares during the period. Jackson Square Partners LLC’s holdings in Sight Sciences were worth $841,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. KCK LTD. acquired a new stake in shares of Sight Sciences in the 4th quarter worth $15,925,000. Barclays PLC increased its position in Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company’s stock worth $317,000 after purchasing an additional 38,248 shares during the last quarter. Millrace Asset Group Inc. purchased a new position in Sight Sciences during the third quarter worth about $874,000. Geode Capital Management LLC boosted its holdings in Sight Sciences by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after purchasing an additional 12,709 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after buying an additional 95,843 shares during the period. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Insider Transactions at Sight Sciences

In other Sight Sciences news, EVP Manohar K. Raheja bought 10,000 shares of Sight Sciences stock in a transaction that occurred on Wednesday, March 12th. The shares were purchased at an average cost of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the transaction, the executive vice president now owns 145,000 shares of the company’s stock, valued at $395,850. This represents a 7.41 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Paul Badawi sold 24,819 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $2.92, for a total value of $72,471.48. Following the completion of the sale, the chief executive officer now directly owns 5,676,331 shares in the company, valued at approximately $16,574,886.52. The trade was a 0.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,014 shares of company stock worth $197,295 over the last ninety days. 28.90% of the stock is currently owned by corporate insiders.

Sight Sciences Stock Up 6.2 %

Shares of NASDAQ SGHT opened at $3.07 on Tuesday. The firm has a 50-day moving average price of $2.76 and a 200 day moving average price of $4.08. The stock has a market capitalization of $157.59 million, a price-to-earnings ratio of -3.01 and a beta of 2.52. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a 52 week low of $2.17 and a 52 week high of $8.45.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). The company had revenue of $19.07 million for the quarter, compared to analysts’ expectations of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same period in the previous year, the business posted ($0.22) EPS. Equities research analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SGHT. Lake Street Capital reduced their price target on shares of Sight Sciences from $3.00 to $2.50 and set a “hold” rating on the stock in a research report on Thursday, March 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Thursday, March 6th. UBS Group decreased their target price on Sight Sciences from $5.50 to $5.00 and set a “buy” rating on the stock in a research note on Monday, January 27th. Piper Sandler dropped their target price on Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a research report on Thursday, March 6th. Finally, Stifel Nicolaus reduced their target price on shares of Sight Sciences from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $3.83.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.